A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

AIROS 8 Sequential Compression Therapy Device Granted FDA 510(k) Clearance

What To Know

  • The inflation and deflation sequences, delivered at the pressure and time prescribed by a physician or lymphedema therapist, move the lymphatic fluid in the correct physiological direction.
  • “We are thrilled to launch our revamped AIROS 8 device and Arm Plus upper extremity product line as it will allow us to expand the number of patients we can help live more comfortably,” says Gerald Makoid, CEO and president of AIROS® Medical.

The AIROS 8 Sequential Compression Therapy device and garment system have received U.S. Food and Drug Administration (FDA) 510(k) clearance. The news was announced today by AIROS® Medical, Inc.

According to various estimates from non-profit organizations, private companies, research studies, and government entities, approximately 4-7 million patients have lymphedema in the United States. Lymphedema is a chronic condition in which damaged or removed lymph nodes creates fluid build-up and swelling most common in the arms, legs, chest, back, and torso. Many patients develop lymphedema after undergoing cancer-related treatments such as radiation and chemotherapy. Post-mastectomy breast cancer patients are among those at the highest risk of developing lymphedema.

The AIROS 8 Sequential Compression Therapy device uses pneumatic air compression to inflate accessory garments worn on the affected area of the body. The inflation and deflation sequences, delivered at the pressure and time prescribed by a physician or lymphedema therapist, move the lymphatic fluid in the correct physiological direction. AIROS Medical has sold the AIROS 8 and its garments since August 2018, but this new FDA 510(k) clearance allows the company to treat breast cancer patients with lymphedema more effectively.

“We are thrilled to launch our revamped AIROS 8 device and Arm Plus upper extremity product line as it will allow us to expand the number of patients we can help live more comfortably,” says Gerald Makoid, CEO and president of AIROS® Medical. “Our team of clinical partners, engineers, and medical device veterans, along with our customers in the durable medical equipment industry, have served the lymphedema community for nearly two decades. We are ecstatic to grow our product offerings and collaborative efforts with healthcare providers to help improve the quality of life for patients living with this chronic condition, lymphedema.”

The AIROS 8 is also available for use with leg garments and arm garments. The leg garments are utilized primarily with patients who have venous complications, including chronic venous insufficiency (CVI), which affects nearly 16 million Americans.

AIROS Medical also manufactures the AIROS 6 device and garment system, which operates in a similar fashion as the AIROS 8. The AIROS 6 model is primarily utilized by patients with Medicare insurance.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

XT-Thrive® Drug Master File (DMF) Accepted by the FDA | Reports X-Therma

X-Therma notes this DMF covers the Chemistry, Manufacturing and Controls (CMC) for this key chemistry innovation, which enables non-toxic cryopreservation for life-saving regenerative medicines.

Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System

Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need.

Transforming Tricuspid Valve Care: FDA Gives Green Light to Abbott’s TriClip™

"The U.S. approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker."

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

This make it one of the only wearable OTC anti-migraine device that is available without a prescription in the U.S.

By using this website you agree to accept Medical Device News Magazine Privacy Policy